基于肾脏转录组学的慢性肾脏病无偏分子分型:迈向精准医学的一步
本研究利用自组织映射无监督机器学习算法,对369例CKD患者和46例健康活体供肾者的肾脏活检转录组数据进行分析,识别出四种新的分子分型(CKD-Blue、CKD-Gold、CKD-Olive、CKD-Plum),并在独立数据集中验证。各分型跨越CKD分期和病理诊断,代表不同生物学通路激活,且疾病进展速率显著不同,CKD-Gold进展最快。尿液蛋白质组学发现25蛋白特征可区分CKD-Gold。
要点
- 基于肾脏转录组的无监督分型可识别四种CKD分子亚型,跨越传统分期和病理诊断。
- CKD-Gold亚型进展最快,校正eGFR后肾衰竭风险比5.6,复合终点风险比4.7。
- 25蛋白尿液特征可区分CKD-Gold,提示非侵入性生物标志物分型的潜力。
核心结论
- 基于肾脏组织转录组学的无偏分型可将CKD分为四种分子亚型,各亚型进展速率显著不同,为精准医学提供新途径。
研究设计与样本
- 研究分析公开的肾脏活检转录组数据,使用自组织映射无监督人工神经网络机器学习算法,对369例CKD患者和46例健康活体供肾者进行分型。
主要发现
- 无偏分层识别出四种新分子分型:CKD-Blue、CKD-Gold、CKD-Olive、CKD-Plum,并在独立CKD和糖尿病肾病数据集中重复验证。
- 各分子分型跨越CKD分期和病理诊断,代表不同生物学通路的转录激活。
- 分子分型间疾病进展速率高度显著不同;CKD-Gold进展快,校正eGFR的Cox回归肾衰竭风险比5.6 [1.01-31.3],肾衰竭或eGFR下降≥40%复合终点风险比4.7 [1.3-16.5]。
- 尿液蛋白质组学显示分子分型间模式不同,25蛋白特征可区分CKD-Gold与其他分子分型。
临床怎么用
- 基于肾脏组织组学的患者分层为无创生物标志物驱动的分型提供途径,未来可能用于临床实施。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Current classification of chronic kidney disease (CKD) into stages using indirect systemic measures (estimated glomerular filtration rate (eGFR) and albuminuria) is agnostic to the heterogeneity of underlying molecular processes in the kidney thereby limiting precision medicine approaches. To generate a novel CKD categorization that directly reflects within kidney disease drivers we analyzed publicly available transcriptomic data from kidney biopsy tissue. A Self-Organizing Maps unsupervised artificial neural network machine-learning algorithm was used to stratify a total of 369 patients with CKD and 46 living kidney donors as healthy controls. Unbiased stratification of the discovery cohort resulted in identification of four novel molecular categories of disease termed CKD-Blue, CKD-Gold, CKD-Olive, CKD-Plum that were replicated in independent CKD and diabetic kidney disease datasets and can be further tested on any external data at kidneyclass.org. Each molecular category spanned across CKD stages and histopathological diagnoses and represented transcriptional activation of distinct biological pathways. Disease progression rates were highly significantly different between the molecular categories. CKD-Gold displayed rapid progression, with significant eGFR-adjusted Cox regression hazard ratio of 5.6 [1.01-31.3] for kidney failure and hazard ratio of 4.7 [1.3-16.5] for composite of kidney failure or a 40% or more eGFR decline. Urine proteomics revealed distinct patterns between the molecular categories, and a 25-protein signature was identified to distinguish CKD-Gold from other molecular categories. Thus, patient stratification based on kidney tissue omics offers a gateway to non-invasive biomarker-driven categorization and the potential for future clinical implementation, as a key step towards precision medicine in CKD.
引用
- Reznichenko A, Nair V, Eddy S, et al. Unbiased kidney-centric molecular categorization of chronic kidney disease as a step towards precision medicine. Kidney Int. 2024. PMID: 38286178. doi:10.1016/j.kint.2024.01.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。